Oncolys BioPharma Inc.
Notice on the NHI Drug Price Listing and Insurance Coverage for Tumor Lysis Virus Telomerase Injection
Drug price listing and insurance coverage approved. Telomerase injection will be marketed through FujiFilm Toyama Chemical starting August 21, 2026. Revenue recognition is expected from the fiscal year ending December 2026.
Key Figures
- Calculated price: 3,102,489 yen (per patient 9,307,467 yen)
- Launch date: August 21, 2026
- Revenue recognition start: Expected from the fiscal year ending December 2026
AI要約
Key points of the news
Formal decision on drug price listing and insurance coverage for Telomerase injection. Sales to commence through the marketing partner, with revenue recognition scheduled from the fiscal year ending December 2026.
Outlook and impact
Anticipated market introduction as coverage begins. However, concrete impact on earnings is under review, and the timing and magnitude of revenue contribution are unknown. Launch date is August 21, 2026, and the price listing indicates the benchmark amount borne by patients.
OncoTherapies BioPharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
